MediGene to Present at Fourth Annual Needham Biotechnology Conference in New York City MARTINSRIED/MUNICH, Germany and SAN DIEGO, May 23 /PRNewswire-FirstCall/ -- The German-American biotech company MediGene AG (German Stock Exchange (Frankfurt), Prime Standard: MDG) [MDGGn.DE] announced today that the Company will be presenting at the Fourth Annual Needham Biotechnology Conference in New York on Wednesday, May 25, 2005 at 4 p.m. local time at the New York Palace Hotel. The presentation will be given by Dr. Peter Heinrich, Chief Executive Officer of MediGene. The presentation will be webcast live and will be accessible through the MediGene website at http://www.medigene.com/. A replay will be available via the website following the live event. MediGene possesses a mature drug pipeline with one drug available on the German market (Eligard(R) for the treatment of prostate cancer) with a pan-European roll out in preparation as well as a number of additional drug candidates in all stages of clinical development (phases I - III): The Polyphenon(R) E Ointment intended for the treatment of a variety of non-melanoma skin tumors has completed two independent clinical phase III trials demonstrating significant efficacy in the treatment of anogenital and perianal warts. MediGene is currently preparing the NDA for submission to the US regulatory authorities in Q3 2005. Line extensions can substantially increase the commercial potential of Polyphenon(R) E. In June 2005, MediGene plans to announce results from a clinical phase II proof of concept study in the indication actinic keratosis. In addition, MediGene owns cutting-edge platform technologies including EndoTAG and oncolytic Herpes Simplex Viruses. The drug candidate EndoTAG-1 follows the already established therapeutic principle of anti-angiogenesis (suppressing tumor vascularization). EndoTAG-1, a novel liposomal formulation of paclitaxel, has already undergone clinical phase I/II trials with more than 100 patients in different cancer diseases. In Q3 2005, MediGene is planning to initiate a phase II trial in pancreatic cancer. The oncolytic Herpes Simplex Virus NV1020 is currently undergoing a phase I/II trial in liver metastases from colorectal carcinoma. About 30 patients will be treated during this trial with results expected by the end of 2006. This press release contains forward-looking statements that involve risks and uncertainties. The forward-looking statements contained herein represent the judgement of MediGene as of the date of this release. These forward- looking statements are no guarantees for future performance, and the forward- looking events discussed in this press release may not occur. MediGene disclaims any intent or obligation to update any of these forward-looking statements. MediGene(TM) is a trademark of MediGene AG, Eligard(R) is a trademark of QLT USA, Inc. (formerly Atrix), Polyphenon(R) E is a trademark of Mitsui Norin. MediGene AG is a publicly quoted (Frankfurt: TecDAX30), German-American biotechnology company located in Martinsried, Germany and San Diego, USA. MediGene is the first German biotech company with a drug on the market. The company has the most mature drug development pipeline in the German biotech industry with oncological drug candidates undergoing clinical phase I - III trials (phase III completed). In addition, MediGene possesses innovative platform technologies with its HSV technology and the newly acquired EndoTAG technology. MediGene's core competence lies in research and development of novel approaches for the treatment of various tumor diseases. Thus MediGene focuses on indications of high medical need and economic opportunities. DATASOURCE: MediGene AG CONTACT: MediGene AG, , Fax: +49-89-85-65-2920; Dr. Michael Nettersheim, Investor Relations, Tel.: +49-89-85-65-2946 Web site: http://www.medigene.com/

Copyright